跳转至内容
Merck
CN
所有图片(1)

主要文件

安全信息

SML1935

Sigma-Aldrich

Nimorazole

≥98% (HPLC)

别名:

4-(2-(5-Nitro-1H-imidazol-1-yl)ethyl)morpholine, K 1900, K-1900, K1900, NSC 107524, NSC-107524, NSC107524

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C9H14N4O3
CAS号:
分子量:
226.23
EC 号:
UNSPSC代码:
12352200
NACRES:
NA.77

质量水平

方案

≥98% (HPLC)

表单

powder

颜色

white to beige

溶解性

DMSO: 30 mg/mL, clear

储存温度

2-8°C

SMILES字符串

[N+](=O)([O-])c1[n](cnc1)CCN2CCOCC2

InChI

1S/C9H14N4O3/c14-13(15)9-7-10-8-12(9)2-1-11-3-5-16-6-4-11/h7-8H,1-6H2

InChI key

MDJFHRLTPRPZLY-UHFFFAOYSA-N

生化/生理作用

A nitroimidazole-based hypoxic cell-radiation sensitizer and anti-infective against Trichomonas vaginalis.
Nimorazole is a nitroimidazole-based hypoxic cell-radiation sensitizer with less toxicity than etanidazole or misonidazole. Under low oxygen (hypoxic) condition, reductive activation of its 5-nitroimidazole moiety leads to enhanced adduct formation with reduced glutathione, which form the basis of cancer/tumour-selective radiation sensitization. Nimorazole is also a known anti-infective agent against trichomoniasis, an infectious disease caused by the protozoan parasite Trichomonas vaginalis.

象形图

Health hazard

警示用语:

Danger

危险声明

危险分类

Muta. 1B - Repr. 2

储存分类代码

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

新产品

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Thomas M Ashton et al.
Nature communications, 7, 12308-12308 (2016-07-28)
Tumour hypoxia renders cancer cells resistant to cancer therapy, resulting in markedly worse clinical outcomes. To find clinical candidate compounds that reduce hypoxia in tumours, we conduct a high-throughput screen for oxygen consumption rate (OCR) reduction and identify a number
Thomas R Wittenborn et al.
Acta oncologica (Stockholm, Sweden), 54(9), 1385-1392 (2015-09-04)
Hypoxia is a characteristic feature of solid tumours that significantly reduces the efficacy of conventional radiation therapy. In this study we investigated the role of hypoxia in a stereotactic radiation schedule by using a variety of hypoxic modifiers in a
Radiotherapy quality assurance of the IAEA-HypoX trial of the accelerated radiotherapy in the treatment of head and neck squamous cell carcinoma with or without the hypoxic radiosensitizer nimorazole.
Mohamed A Hassan Metwally et al.
Acta oncologica (Stockholm, Sweden), 54(9), 1673-1677 (2015-09-24)

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门